Eyeworld Daily News

2019 ASCRS•ASOA San Diego Daily Monday

EyeWorld Today is the official daily of the ASCRS Symposium & Congress. Each issue provides comprehensive coverage editorial coverage of meeting presentations, events, and breaking news

Issue link: https://daily.eyeworld.org/i/1116418

Contents of this Issue

Navigation

Page 5 of 64

Glaukos 5 Denise Visco Keith Walter Steve Silverstein Eric Donnenfeld Mitch Jackson Your name here John Hovanesian Inder Paul Singh Richard Lindstrom John Sheppard Bob Osher James Loden Sheri Rowen Cynthia Matossian Cathleen McCabe Cynthia Matossian Eric Donnenfeld Mitch Jackson John Sheppard Sheri Rowen Frank Bucci INDICATIONS AND USAGE OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain. IMPORTANT SAFETY INFORMATION OMIDRIA must be added to irrigating solution prior to intraocular use. OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma. The most commonly reported adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation. Please see the Full Prescribing Information for OMIDRIA at www.omidria.com/prescribinginformation. You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. References: 1. Omeros survey data on fi le. 2. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2017. 3. Al-Hashimi S, Donaldson K, Davidson R, et al; for ASCRS Refractive Cataract Surgery Subcommittee. Medical and surgical management of the small pupil during cataract surgery. J Cataract Refract Surg. 2018;44:1032-1041. These cataract surgeons use OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% for less stress, pure success in their O.R. day 1 What about you? OMIDRIA helps your cataract surgery by inhibiting prostaglandin release to block inflammation and maintain iris tone, preventing miosis and reducing postoperative pain for your patients. 2,3 Experience less stress in your O.R. day with OMIDRIA. 1 OMEROS®, the OMEROS logo®, OMIDRIA®, and the OMIDRIA logo® are registered trademarks of Omeros Corporation. © Omeros Corporation 2019, all rights reserved. 2019-001 ™ These cataract surgeons use OMIDRIA® (phenylephrine and ketorolac intraocular less stress, pure OMIDRIA helps your cataract surgery by inhibiting prostaglandin release to block inflammation and maintain iris tone, preventing miosis and reducing postoperative Experience less stress in your O.R. day with OMIDRIA. 1 ™ inflammation and maintain iris tone, preventing miosis and reducing postoperative The healthcare professionals portrayed in this advertisement are consultants of Omeros Corporation. ™

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld Daily News - 2019 ASCRS•ASOA San Diego Daily Monday